Latest News

Comstock Resources (CRK) is set to report quarterly earnings on February 11, 2026, an event drawing attention as investors weigh its 47.75% revenue growth versus peers against higher debt and an expected EPS of $0.11. See our latest analysis for Comstock Resources. At a share price of $20.42, Comstock Resources has seen a 9.12% decline in its 7 day share price return and a 19.03% decline over 90 days. However, its 1 year total shareholder return of 10.86% and 5 year total shareholder return...

Why Versant Media Group Is On Investors’ Radar Today Versant Media Group (VSNT) has drawn fresh attention after a period of weak share performance, with the stock down about 16% over the past month and around 38% year to date. For investors tracking U.S. media names, this recent slide, alongside reported revenue of $6,801 and net income of $1,125, raises questions about how the company’s cable networks and digital platforms are being valued in today’s market. See our latest analysis for...

What Regeneron’s Recent Trading Says About Investor Focus Regeneron Pharmaceuticals (REGN) has seen mixed share performance recently, with a 3.3% decline over the past day and a small slip over the past week, but a positive move across the past 3 months. Over the past month the stock has fallen about 5.2%, while its 1 year total return of 14.1% and 5 year total return of 57.9% highlight a very different picture for longer term holders. See our latest analysis for Regeneron...

NP3 Fastigheter (OM:NP3) just released its fourth quarter and full year 2025 results, with higher reported sales, net income and earnings per share. This puts the latest earnings call in clear focus for investors. See our latest analysis for NP3 Fastigheter. Following the earnings release and call on 6 February 2026, NP3 Fastigheter’s share price has moved to SEK272.0, with a 1-day share price return of 1.87% and a 7-day share price return of 4.62%. Its 1-year total shareholder return of...

Recent commentary around Prologis (PLD) has zeroed in on two forces pulling in different directions: softer 2025 logistics rents with talk of a rebound in 2026, and renewed attention on legal risks. See our latest analysis for Prologis. The recent mix of legal headlines and new data center partnerships comes against a backdrop of firm share price momentum, with a 30 day share price return of 8.56% and a 1 year total shareholder return of 19.47% suggesting that investors are reassessing both...

Event context and recent performance snapshot Franklin Resources (BEN) has drawn fresh attention after recent trading, with the share price at $28.16 and total return figures of 18.3% year to date and 47.8% over the past year. See our latest analysis for Franklin Resources. The recent 1-day share price return of 1.73% and 90-day share price return of 22.17% sit alongside a 1-year total shareholder return of 47.79%, suggesting momentum has been building rather than fading. If Franklin...

EQT (OM:EQT) is back in focus after its EQT Life Sciences arm co led a $39 million Series A round for Aerska, a biotech developing RNA medicines for neurological diseases using brain shuttle technology. See our latest analysis for EQT. EQT’s recent Aerska funding and infrastructure deal interest come after a tougher few months for the share price, with a 30 day share price return of 15.81% decline and a 1 year total shareholder return of 16.12% decline, while longer term total shareholder...

If you are wondering whether JFrog shares at about US$53.20 still offer value, you are not alone. This article breaks down what that price might really represent. The stock has been volatile, with a 2.7% return over the last 7 days, a 10.2% decline over 30 days, a 10.7% decline year to date, and a 48.0% return over 1 year, alongside a 119.8% return over 3 years and a 23.2% decline over 5 years. Recent coverage of JFrog has focused on its role in software development tooling and how investors...

KBR (KBR) is back in focus after a run of new U.S. defense and space contracts, including firm-fixed-price awards totaling US$103 million and an additional US$77 million task order from the U.S. Space Force. See our latest analysis for KBR. Despite the fresh U.S. defense and space awards, KBR’s recent trading tells a mixed story, with an 8.12% year to date share price return contrasting with a 1 year total shareholder return decline of 18.90%. This hints at improving short term momentum...

If you are wondering whether Kimco Realty's current share price lines up with its underlying value, this article will walk through what the numbers are saying and where the market might be getting ahead of itself or selling it short. Kimco Realty shares recently closed at US$22.19, with returns of 6.2% over 7 days, 8.7% over 30 days, 10.6% year to date, 4.0% over 1 year, 19.8% over 3 years and 55.9% over 5 years. This gives useful context before you weigh up the valuation. Recent coverage on...

In early February 2026, PTC Inc. reported first-quarter fiscal 2026 results showing higher revenue and earnings compared to a year earlier, raised its full-year 2026 revenue and earnings guidance, and confirmed it had repurchased about 2.33% of its shares under a buyback announced in November 2024. This combination of stronger recent performance, more optimistic full-year forecasts, and an ongoing capital return program highlights how management is aligning operational progress with...

International Petroleum (TSX:IPCO) FY 2025 Results: Slower Finish To A Profitable Year International Petroleum (TSX:IPCO) closed FY 2025 with Q4 revenue of US$175.0 million and a basic EPS loss of US$0.05, capping off a year in which trailing twelve month revenue was US$681.5 million and EPS came in at US$0.25. Over recent periods, the company has seen quarterly revenue move between US$157.8 million and US$198.1 million and quarterly EPS swing from a profit of US$0.19 to a loss of US$0.05,...

Earnings setback and dividend affirmation come into focus Swatch Group (SWX:UHR) is in the spotlight after full year 2025 results showed sales of CHF 6,280 million and net income of CHF 3 million, alongside confirmation of an annual dividend of CHF 4.50 per share. See our latest analysis for Swatch Group. The annual results and dividend affirmation arrived alongside strong near term momentum, with a 1 day share price return of 2.43% and a 30 day share price return of 12.53%. However, the 3...

Why Celanese’s Latest Price Moves Matter for Investors Celanese (CE) is raising prices for acetic acid, vinyl acetate monomer, and related derivatives across the Western Hemisphere, a change that takes effect immediately or as existing contracts allow. For you as an investor, this type of pricing shift can influence revenue mix, margins, and customer relationships, especially in segments where Celanese supplies key inputs into industrial and consumer applications. See our latest analysis for...

Analyst coverage sparks fresh attention on NextDecade Capital One Financial has initiated coverage on NextDecade (NEXT) with a buy rating, putting fresh attention on the liquefied natural gas developer and its Rio Grande LNG and carbon capture projects in Texas. See our latest analysis for NextDecade. NextDecade's share price has climbed 6.3% over the past week and 10.0% over the past month to US$5.38, although the 1 year total shareholder return shows a 32.1% decline and the 5 year total...

In the past week, Edwards Lifesciences reported Q4 2025 sales of US$1,569.6 million and full-year 2025 sales of US$6.07 billion, alongside issuing 2026 guidance calling for first-quarter sales of US$1.55 billion to US$1.63 billion and full-year EPS of US$2.90 to US$3.05. While revenue continued to grow, the sharp drop in quarterly and full-year net income and EPS highlights how margin pressure and one-off factors are shaping Edwards’ profit profile as it invests behind its Structural Heart...

Novo Nordisk (CPSE:NOVO B) has filed a US patent lawsuit against Hims & Hers over a compounded oral semaglutide weight loss pill that used the active ingredient in Wegovy and Ozempic. The telehealth company withdrew the product within days after regulatory pressure from the FDA and the Department of Health and Human Services. Novo Nordisk is seeking a permanent injunction to limit copycat versions and protect its intellectual property in the obesity drug market. Novo Nordisk, best known for...

In January 2026, Sumitomo Mitsui Trust Group, Inc. reported results for the nine months ended December 31, 2025, with net income rising to ¥266,673 million and basic earnings per share from continuing operations increasing to ¥378.37. An interesting aspect of this update is that net interest loss narrowed to ¥38,032 million, highlighting improved earnings despite ongoing pressure on interest income. With earnings and per-share profitability higher over the nine-month period, we will now...

Teijin earnings trigger fresh look at the stock Teijin (TSE:3401) just posted nine month results to December 31, 2025, reporting sales of ¥659,878 million and a shift from prior year profit to a net loss of ¥58,970 million. The report included basic and diluted loss per share of ¥305.81 from continuing operations, compared with basic and diluted earnings per share of ¥264.66 in the same period a year earlier. See our latest analysis for Teijin. Despite the swing to a net loss, Teijin’s recent...

Pinterest (NYSE:PINS) has appointed Kecia Steelman, CEO of Ulta Beauty, to its Board of Directors. The company is rolling out a global restructuring plan that includes workforce and office space reductions. Management is prioritizing investment in AI technology to support shopping and visual discovery on the platform. Pinterest runs a visual discovery and social media platform built around images, search and idea curation, with a growing focus on shopping experiences. Across the sector,...

In early February 2026, Iovance Biotherapeutics reported real-world data for its commercial Amtagvi (lifileucel) therapy in advanced melanoma, showing what it called a best-in-class profile with unprecedented response rates, while reiterating extensive regulatory, manufacturing, and commercialization risks in its latest disclosures. The company’s detailed risk discussion highlights how fragile this apparent clinical success could be, with uncertainties around ex-U.S. approvals, manufacturing...

Why Unilever shares are on investor watch now Unilever (LSE:ULVR) has caught investor attention after a period of solid recent share performance, with the stock showing gains over the past week, month and past 3 months. See our latest analysis for Unilever. At a share price of £52.44, Unilever’s recent momentum is strongest over the past month, with a 10.54% 1 month share price return. Its 1 year total shareholder return of 7.43% and 5 year total shareholder return of 46.26% point to a...

Recent coverage around potential US cannabis regulatory shifts, including possible rescheduling to Schedule III and the SAFER Act, has brought Innovative Industrial Properties (IIPR) back into focus for income oriented real estate investors. See our latest analysis for Innovative Industrial Properties. IIPR’s latest share price of $47.99 sits against a backdrop of a 30 day share price return of 5.16% and a year to date share price return of 2.99%. The 1 year total shareholder return of 25.89%...

Bank of Montreal (TSX:BMO) is back in focus after analysts adjusted earnings estimates to reflect stronger trading expectations and a $200 million restructuring charge, along with leadership changes aimed at growing its global corporate banking business. See our latest analysis for Bank of Montreal. Those trading expectations and leadership changes are landing in a buoyant share price backdrop, with Bank of Montreal’s CA$197.49 share price sitting on a 30 day share price return of 7.01% and a...